A Phase 3 interventional study of Placebo and Flurbiprofen in Pharyngitis, sponsored by Reckitt Benckiser LLC. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-21.
Sponsored by Reckitt Benckiser LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Pharyngitis with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Pharyngitis · United States.
Among the 41 studies in Pharyngitis with a site in United States, this one is the 18th largest by enrollment of the 35 interventional ones that give a count, is one of 4 that started in 2009, is one of 18 in phase 3, and was the 13th registered.
227 studies on the registry are indexed under Pharyngitis; 36 are open to participants now.
Browse Pharyngitis studies →4 of the 41 studies in Pharyngitis with a site in United States are open now. Recruiting first, the newest first:
SalivIQ Diagnostics, Inc. · Sites in United States
Ages 3+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 1 mo–99 yrs
University of Pittsburgh · Sites in United States
Ages 6 mo–24 mo
The University of Texas Health Science Center, Houston · Sites in United States
Ages 3–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 19 Pharyngitis studies recruiting now, 5 (26%) set no upper age limit and 10 (53%) stop at 75 or younger; 8 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 4 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 204 is above the median of 144 across 189 interventional studies indexed under Pharyngitis.
Median enrollment 204 across the 35 interventional studies, 587 across the 6 observational. Of the 33 that completed or were terminated, 13 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 41 have an industry lead sponsor. The 10 most frequent:
This study is registered under Reckitt Benckiser LLC, one of the names counted as Reckitt. Under that name alone:
Reckitt Benckiser LLC is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Reckitt has 3 studies filed under Pharyngitis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pharyngitis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07891728SalivIQ Diagnostics, Inc.A Multicenter Evaluation of SalivIQ™ Strep A for Detecting Group A Streptococcus From Saliva and Throat Swabs in Patients With Acute Pharyngitis | 2027-01-31 |
Add it to your calendar (.ics) → With an account.
Among the 41 studies in Pharyngitis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purposes of this study is to demonstrate the analgesic efficacy of flurbiprofen 8.75 mg lozenge compared to its vehicle lozenge and to demonstrate the safety of the flurbiprofen lozenge throughout the course of treating sore throat due to acute pharyngitis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants sucked flurbiprofen 8.75mg lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
Drug: Flurbiprofen
Participants sucked vehicle placebo lozenge every 3-6 hours up to 5 lozenges a day as needed for pain for 7 days.
Drug: Placebo
Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2)
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
Time frame: baseline (pre-dose), 2 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2)
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
Time frame: baseline (pre-dose), 2 hours post-dose (every 10 minutes until hour 2)
Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
Time frame: baseline (pre-dose), 24 hours post-dose (every 10 minutes until hour 2, every 30 minutes until hour 6, hourly from 7-24 hours)
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.
Time frame: baseline (pre-dose), 2 hours post-dose (at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours)
Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS.
Time frame: baseline (pre-dose), 24 hours post-dose (1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, 2 hours, 2½ hours, 3 hours, 3½ hours, 4 hours, 4½ hours, 5 hours, 5½ hours, and 6 hours after the first dose, hourly from 7-24 hours)
Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8
Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms.
Time frame: Baseline (pre-dose), 24 hours post-dose
Practitioner's Assessment of Pharyngeal Inflammation (P.A.I.N.) Scores at 24 Hours After Initial Dose
P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation.
Time frame: 24 hours post-dose
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at 24 Hours After Initial Dose
Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.
Time frame: 24 hours
Participant Satisfaction Scores 24 Hours After Initial Dose
After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.
Time frame: 24 hours
Investigators' Clinical Assessment (CLIN) Of Study Medication as a Treatment for Sore Throat at the End of the Study (Day 7)
Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.
Time frame: Day 7
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation.
Time frame: baseline (pre-dose), 24 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-24)
Sore Throat Relief Rating Scale (STRRS) At 2 Hours After Initial Dose
Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now."
Time frame: 2 hours
Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) at Each Post-Dose Time Point Until the Time Point at Which Comparison of the Arms Yielded a P-value <=0.05
Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec
Time frame: baseline (pre-dose), up to 23 hours post-dose (every 2 minutes for one hour; every 10 minutes until hour 2; every 30 minutes until hour 6; and every hour the participant was awake between hours 7-23)
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication.
Time frame: 2 hours
Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL)
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours.
Time frame: 6 hours
| Milestone | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Started | 102 | 102 |
| Completed | 93 | 95 |
| Not completed | 9 | 7 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Protocol violation | 0 | 1 |
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID24 was calculated as the sum of the time-weighted pain intensity differences from baseline until 24 hours. The full range was -114609 (complete pain relief within 2 minutes of dosing that lasts 24 hours) to 29191 (maximum pain within 2 minutes lasting 24 hours) using the mean baseline STPIS. Participants with a last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication, all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24) | -473.7 ± 45.4428 | -322.3 ± 45.6708 |
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. SPID2 was calculated as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dosing. The full range was -9405 (complete pain relief within 2 minutes of dosing that lasts 2 hours) to 2395 (maximum pain within 2 minutes lasting 2 hours) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed post dose), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (recorded or derived due to rescue) were imputed using linear interpolation assuming the time of the missing assessment to be the nominal time since initial dose.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 2 Hours Post-baseline (STPIS SPID2) | -43.4 ± 39.20 | -23.5 ± 29.52 |
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and 2 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 2 hours post dose. The full range was -9192 (no difficulty swallowing within 10 minutes of dosing that lasts 2 hours) to 2808 (maximum difficulty swallowing within 10 minutes lasting 2 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 2 Hours From Baseline | -39.1 ± 38.64 | -16.6 ± 29.34 |
Participants were asked to evaluate his/her difficulty swallowing (dysphagia) using a 100-mm visual analog scale at Baseline and until 24 hours post dose. Participants were instructed to swallow and "Place a line on the scale that best characterizes how difficult it is to swallow now." A mark at 0-mm indicated no difficulty and 100-mm indicated very difficult. Data is reported as the sum of the time-weighted pain intensity differences from baseline until 24 hours post dose. The full range was -110304 (no difficulty swallowing within 10 minutes of dosing that lasts 24 hours) to 33696 (maximum difficulty swallowing within 10 minutes lasting 24 hours) using the baseline DSS value. Missing values of DSS with non-missing values at assessments before and after were calculated using linear interpolation.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Summed Differences in Difficulty Swallowing Scale (DSS) During the Initial 24 Hours From Baseline | -460.8 ± 498.79 | -274.3 ± 455.35 |
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and at 1 hour, 70 minutes, 80 minutes, 90 minutes, 100 minutes, 110 minutes, and 2 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 2 hours was -9336 (throat did not feel swollen at all within 1 hour of dosing and lasted 2 hours) to 2664 (maximum swollen throat reported within 1 hour and lasting 2 hours) using the mean baseline SwoTS.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 2 Hours From Baseline | -39.9 ± 39.63 | -20.1 ± 27.28 |
The participant was asked to evaluate how swollen his/her throat felt using a 100-mm visual analog scale at Baseline and specified timeframes until 24 hours. The patient was instructed to swallow and "Place a line on the scale that best characterizes how swollen your throat feels now." A mark at 0-mm indicated not swollen and 100-mm indicated very swollen. The full range of the sum of the time-weighted swollen throat differences from baseline until 24 hours was -112032 (throat did not feel swollen at all within 1 hour of dosing and lasted 24 hours) to 31968 (maximum swollen throat reported within 1 hour and lasting 24 hours) using the mean baseline SwoTS.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Summed Differences in Swollen Throat Scale (SwoTS) During the Initial 24 Hours From Baseline | -472.2 ± 521.89 | -355.2 ± 432.04 |
Tonsillo-Pharyngitis Assessment, or TPA, is an index of seven clinical features of the pain-producing condition itself, pharyngeal inflammation. The clinical features concern temperature, oropharyngeal color, size of tonsils, number of enanthems, largest size of cervical lymph node, number of lymph nodes, and maximum tenderness of lymph nodes. Each variable was rated on a scale of 0-3, with 0 representing the normal value, and 3 representing severe inflammation. The seven values are added together to create the TPA, ranging from 0-21. Negative change values represent improvement of symptoms.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Change From Baseline at 24 Hours in the Tonsillo-Pharyngitis Assessment (TPA) Scores in Participants With Baseline TPA Scores >=8 | -1.2 ± 2.61 | -2.0 ± 2.71 |
P.A.I.N is a four step scale in which physicians rate the severity of pharyngeal inflammation: No inflammation, mild, moderate and severe inflammation.
| participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| No inflammation | 0 | 1 |
| Mild inflammation | 48 | 42 |
| Moderate inflammation | 42 | 50 |
| Severe inflammation | 11 | 7 |
Investigators assessed the effectiveness of study medication on the patient's sore throat at 24 hours following initial dose by answering the following question: "Considering the patient's response to the study medicine over the past 24 hours, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Poor | 15.8 | 38.0 |
| Fair | 34.7 | 28.0 |
| Good | 19.8 | 18.0 |
| Very Good | 13.9 | 13.0 |
| Excellent | 15.8 | 3.0 |
After 24 hours of treatment, participants rated their satisfaction with the treatment on a 7-step scale from extremely dissatisfied to extremely satisfied.
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Extremely dissatisfied | 5.0 | 10.0 |
| Very dissatisfied | 6.9 | 20.0 |
| Dissatisfied | 11.9 | 14.0 |
| Somewhat satisfied | 29.7 | 28.0 |
| Satisfied | 20.8 | 17.0 |
| Very satisfied | 23.8 | 9.0 |
| Extremely satisfied | 2.0 | 2.0 |
Investigators assessed the effectiveness of study medication on the patient's sore throat at the end of the study by answering the following question: "Considering the patient's response to the study medicine over the past 7 days, how do you rate the study medicine as a treatment for sore throat?" Responses were poor, fair, good, very good or excellent.
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Poor | 11.8 | 31.6 |
| Fair | 28.0 | 34.7 |
| Good | 30.1 | 14.7 |
| Very Good | 17.2 | 14.7 |
| Excellent | 12.9 | 4.2 |
STPIS measures sore throat pain intensity on a 100-mm visual analog scale completed by participants. A mark at 0-mm indicates no pain upon swallowing and 100-mm indicates severe pain. For the subgroup of patients with moderate/severe pharyngeal inflammation at baseline, SPID24 was calculated as the sum of the time weighted pain intensity differences from baseline until 24 hours. Taking inclusion criteria into account, the full range was -116196 (no pain at any post-dose time (0) - average baseline) to 27804 (maximum possible pain (100) - average baseline). Participants with their last recorded time point \<21 hours were considered Not Evaluable. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments were imputed using linear interpolation.
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale Over 24 Hours Post-baseline (STPIS SPID24) For Participants With Baseline Practitioner's Assessment of Pharyngeal Inflammation (PAIN) of Moderate or Severe | -451.4 ± 491.05 | -283.4 ± 378.06 |
Participants used a 6-category relief scale (no relief to complete relief) to grade the relief of his/her throat pain. The patient was instructed to swallow and: "Considering how your throat felt before you took the study medicine, circle the phrase that best describes the relief of your sore throat now."
| percentage of participants | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| No relief | 18.6 | 45.1 |
| Slight relief | 23.5 | 24.5 |
| Mild relief | 23.5 | 11.8 |
| Moderate relief | 20.6 | 13.7 |
| Considerable relief | 13.7 | 4.9 |
| Complete relief | 0 | 0 |
Data reported in summary form in Primary Outcome #1 are reported here at each post-dose timepoint until the comparison resulted in a P-value \<=0.05 between the two treatment arms. STPIS was used to measure sore throat pain intensity using a 100-mm visual analog scale completed by participants that measures "pain on swallowing" (odynophagia). A mark at 0-mm indicates no pain and 100-mm indicates severe pain. The full range of the scale varies by timepoint due to the time weighting sum of SPID. The full scale at 40 minutes post dose was -3188 (complete pain relief within 2 minutes of dosing that lasts 40 minutes) to 812 (maximum pain within 2 minutes lasting 40 minutes) using the mean baseline STPIS. If a participant used rescue medication (acetaminophen 650mg was allowed as needed), all post-rescue STPIS values in the 24-hour interval were assigned the baseline value for STPIS. Missing scores of STPIS with non-missing STPIS scores at earlier and later assessments (rec
| units on a scale | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Minutes post dose: 2 | -0.1 ± 0.26 | -0.2 ± 0.33 |
| Minutes post dose: 4 | -0.3 ± 0.62 | -0.4 ± 0.69 |
| Minutes post dose: 6 | -0.6 ± 1.05 | -0.8 ± 1.14 |
| Minutes post dose: 8 | -0.9 ± 1.56 | -1.2 ± 1.60 |
| Minutes post dose: 10 | -1.4 ± 2.10 | -1.6 ± 2.11 |
| Minutes post dose: 12 | -1.9 ± 2.68 | -2.1 ± 2.59 |
| Minutes post dose: 14 | -2.4 ± 3.30 | -2.5 ± 3.08 |
| Minutes post dose: 16 | -3.0 ± 3.94 | -2.9 ± 3.56 |
| Minutes post dose: 18 | -3.5 ± 4.56 | -3.3 ± 4.01 |
| Minutes post dose: 20 | -4.1 ± 5.19 | -3.7 ± 4.47 |
| Minutes post dose: 22 | -4.7 ± 5.83 | -4.1 ± 4.95 |
| Minutes post dose: 24 | -5.2 ± 6.46 | -4.5 ± 5.43 |
| Minutes post dose: 26 | -5.9 ± 7.12 | -4.9 ± 5.69 |
| Minutes post dose: 28 | -6.5 ± 7.76 | -5.3 ± 6.37 |
| Minutes post dose: 30 | -7.2 ± 8.41 | -5.8 ± 6.87 |
| Minutes post dose: 32 | -7.9 ± 9.09 | -6.2 ± 7.36 |
| Minutes post dose: 34 | -8.6 ± 9.77 | -6.6 ± 7.87 |
| Minutes post dose: 36 | -9.3 ± 10.45 | -7.1 ± 8.37 |
| Minutes post dose: 38 | -10.1 ± 11.14 | -7.5 ± 8.87 |
| Minutes post dose: 40 | -10.8 ± 11.80 | -7.9 ± 9.38 |
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. An alternative definition of STPIS time to onset of relief was the time from initial dose to the time the participant reaching DIL for at least 30 minutes. Data were censored if DIL was not achieved by 120 minutes following initial dose. Definite improvement must also occur prior to re-dosing or using rescue medication.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement | NA (NA to NA) | NA (NA to NA) |
As part of a protocol amendment, some participants defined a definite improvement level (DIL) relative to their actual pretreatment STPIS on the 100-mm visual analog scale. This was done after completing the 7 day trial. The time of first achieving DIL for 30 minutes within 6 hours (or until rescue or re-dosing) post-dosing will be determined. And the time falling below DIL within 6 hours will be determined. Duration is then defined as the time from first DIL until falling below DIL. Duration was set to zero if the STPIS score does not reach the DIL for at least 30 minutes for STPIS during the 6 hours.
| minutes | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| Kaplan-Meier Estimates for Sore Throat Pain Intensity Scale (STPIS) Time to Definite Improvement Duration of Relief Using Participant-Defined Definite Improvement Levels (DIL) | 75.2 ± 102.41 | 29.4 ± 65.06 |
Collected over Initial dose up to Day 7. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Flurbiprofen 8.75 mg Lozenge | — | 0/102 (0%) | 36/102 (35.3%) |
| Placebo Lozenge | — | 0/102 (0%) | 33/102 (32.4%) |
| Event | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge |
|---|---|---|
| HeadacheNervous system disorders | 3/102 | 6/102 |
| NauseaGastrointestinal disorders | 2/102 | 5/102 |
| TonsillitisInfections and infestations | 4/102 | 3/102 |
| ParaesthesiaNervous system disorders | 4/102 | 0/102 |
| Abdominal pain upperGastrointestinal disorders | 3/102 | 0/102 |
| Aphthous stomatitisGastrointestinal disorders | 3/102 | 2/102 |
| Oral painGastrointestinal disorders | 3/102 | 0/102 |
| PainGeneral disorders | 0/102 | 3/102 |
| Otitis mediaInfections and infestations | 3/102 | 0/102 |
| Throat irritationRespiratory, thoracic and mediastinal disorders | 3/102 | 0/102 |
| Age, Continuous(years) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 19.8 ± 1.48 | 19.8 ± 1.47 | 19.8 ± 1.47 |
| Sex: Female, Male(Participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Female | 54 | 63 | 117 |
| Male | 48 | 39 | 87 |
| Race/Ethnicity, Customized(participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 5 | 11 |
| Not Hispanic or Latino | 96 | 97 | 193 |
| Race/Ethnicity, Customized(participants) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Asian | 3 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African | 5 | 2 | 7 |
| White | 92 | 95 | 187 |
| Multi-racial | 0 | 1 | 1 |
| Other, not specified | 2 | 2 | 4 |
| Sore Throat Pain Intensity Scale (STPIS)(units on a scale) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 78.8 ± 8.56 | 80.5 ± 7.92 | 79.7 ± 8.27 |
| Difficulty Swallowing Scale (DSS)(units on a scale) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 76.9 ± 12.41 | 76.3 ± 11.04 | 76.6 ± 11.72 |
| Swollen Throat Scale (SwoTS)(units on a scale) | Flurbiprofen 8.75 mg Lozenge | Placebo Lozenge | Total |
|---|---|---|---|
| Mean | 76.6 ± 13.98 | 79.0 ± 12.05 | 77.8 ± 13.07 |
The record gives a start of Nov 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2017, 6 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flurbiprofen